Pirenzepine topical - WinSanTor

Drug Profile

Pirenzepine topical - WinSanTor

Alternative Names: Topical pirenzepine - WinSanTor; WST 057; WST-1; WST01; WST1/analgesic; WST57

Latest Information Update: 03 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of California, San Diego; University of Manitoba
  • Developer WinSanTor
  • Class Antidementias; Antiulcers; Benzodiazepinones; Gastric antisecretories; Small molecules
  • Mechanism of Action Muscarinic M1 receptor antagonists; Sensory receptor cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Diabetic neuropathies
  • Research Neuropathic pain

Most Recent Events

  • 03 Aug 2017 Chemical structure information added
  • 26 Apr 2017 WinSanTor plans a phase I trial in Healthy volunteers in Australia (ACTRN12617000535370p)
  • 17 Jan 2017 WinSanTor plans a proof-of-concept phase II trial for diabetic peripheral chemo-induced neuropathies in Europe, Canada and China (WinSanTor pipeline, June 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top